preventable health costs.2-4
The cardioprotective medication (antiplatelet agents,
b-blockers, statins and/or angiotensin-converting enzyme
inhibitors (ACEI)) was associated with the reduction of
relative risk of mortality by acute coronary syndrome (ACS)
in 80% compared to the treatment with placebo. In the
United States of America, it is estimated that secondary
prevention contributed to a 11% decrease in the number of
deaths by ACS